Did Sarep­ta re­al­ly score a suc­cess in the lat­est cut of their next-gen Duchenne MD drug? As usu­al, that's a lit­tle com­pli­cat­ed

Sarep­ta boost­ers have been keep­ing their fin­gers crossed that the read­out on their new-and-im­proved 30 mg/kg ap­proach to ex­on-skip­ping for Duchenne mus­cu­lar dy­s­tro­phy pa­tients will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER